MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (1370)	3/31/2001 11:28:42 AM
From: seminole	of 1826

Prostate biz.yahoo.com In one presentation, complete regressions of hormone-refractory human DU-145 prostate tumors growing in nude mice were reported when irofulven was used in combination with Taxotere® (docetaxel). Complete regressions were observed in 17 of 20 animals administered the drugs in combination, whereas Taxotere alone produced no complete regressions and a submaximal dose of irofulven produced complete regressions in two of 10 animals. MGI now plans to initiate a Phase 1 clinical trial to evaluate this promising drug combination in cancer patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next